Grifols, S.A. (GIFLF)
Grifols, S.A. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Barcelona, CT, ES. The stock last traded at $11.76, up 0.00% on the session, giving a market capitalisation of $8.00B. On trailing twelve-month figures it carries a trailing P/E of 15.04, a net margin of 6.1%. Its beta of 1.19 implies it has historically moved more than the broad market.
Grifols, S.A., a company established in Barcelona, Spain, in 1940, specializes in the sourcing, production, and sale of therapeutic products, principally derived from blood plasma. Its diverse activities are structured across five main divisions. The Bioscience division spearheads the research, development, manufacturing, and commercialization of plasma-derived medications and novel solutions designed to treat chronic, rare, widespread, and life-threatening diseases. Its portfolio includes immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. Through its Hospital division, Grifols supplies non-biological pharmaceutical products and medical provisions, encompassing clinical nutrition, intravenous therapies, and various medical devices. The Diagnostic division focuses on developing and distributing diagnostic tools that support healthcare professionals throughout the patient journey, from prevention and screening to accurate diagnosis, prognosis, and continuous treatment monitoring. Additionally, the Bio Supplies division furnishes crucial biological materials for scientific research, clinical trials, and the production of pharmaceutical and diagnostic goods. Grifols' products and services are employed by healthcare providers to both diagnose and manage a range of conditions, such as hemophilia, immune deficiencies, and infectious diseases. The company caters to a broad spectrum of public and private customers, including wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care facilities, and national health systems. Grifols also engages in a technology collaboration agreement with Mondragon.
Grifols, S.A. is most often compared with the following Healthcare names: